U.S. CDC Says Flu, Covid-19, RSV Illnesses Are At Low Levels Right Now Overall In U.S., But We Expect Them To Increase In Coming Weeks; Expects Hospitalizations For Flu And Covid-19 To Start Increasing In Coming Weeks
AZNUBS Upgrades AstraZeneca to Neutral
AZNGRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer ctDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo
AZNAstraZeneca's Tagrisso (Osimertinib) Has Been Recommended For Approval In The European Union For Adult Patients With Locally Advanced, Unresectable Non-small Cell Lung Cancer With Unresectable Epidermal Growth Factor Receptor-Mutated Lung Cancer
AZNEuropean And US Vaccine Stocks Are Under Pressure - Here's WHy
AZNVaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts.
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
AZNAltria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38.
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill
AZNTrump's decision to appoint Kennedy, known for his vaccine skepticism, has sparked significant attention.
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower
AZNTrump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape policies and affect vaccine stocks.
Soros Fund Management 13F Shows Added Put Position In SPDR S&P 500 ETF With 2,123,000 Shares; Added Stake In Smurfit Westrock With 6,896,971 Shares; Added Put Position In Ishares Russell 2000 ETF With 800,000 Shares; Added Stake In Microchip Technology Co
AZNAstraZeneca Says Arrests Of Current And Former Staff Mentioned By CEO In September To Bloomberg Are A Third Issue, Unrelated To Medical Insurance And Wang Investigations; Sought To Quell Concerns About China Business After Report Of Broader Probe Into Pot
AZNWhy Is AstraZeneca Stock Sinking On Tuesday?
AZNChinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock falls around 7%
AstraZeneca Comments On Share Price Movement; Says As A Matter Of Policy, We Do Not Comment On Speculative Media Reports Including Those Related To Ongoing Investigations In China. If Requested, We Will Fully Cooperate With The Chinese Authorities. We Con
AZNReported Earlier, 'AstraZeneca Insurance Fraud Involves Dozens of Senior Executives in China, Source Says' - Yicai Global
AZNSmart Money Is Betting Big In AZN Options
AZNAstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug
AZNAstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety, tolerability, and convenient dosing.
AstraZeneca Meet The Management: Weight Management Virtual Event Began At 10:00 am EST
AZN'AstraZeneca Says Experimental Obesity Pill Safe And Tolerable In Early-Stage Trial' - Bloomberg News; Shares Spike Higher
AZNHere's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
AZN'Disease Experts Predict A Small Rise In Covid-19 Cases This Summer' - CNBC
AZNAstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion
AZNAstraZeneca aims to boost its revenue from $45.8 billion in 2023 to $80 billion by 2030. Key growth drivers include expanding oncology, biopharmaceuticals, rare disease portfolios, and launching 20 new medicines.
AstraZeneca Aims For $80B Revenue By 2030 With Bold Plans For 20 New Medicines And Sustainable Growth
AZNPfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
AZNA Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment.
AstraZeneca Plans $1.5B Manufacturing Facility For Antibody Drug Conjugates In Singapore, AstraZeneca Expects To Begin Design And Construction By The End Of 2024, With Targeted Operational Readiness From 2029
AZNPuma Biotechnology Says Jury Verdict Was Entered In Favor Of Wyeth, And Against AstraZeneca; Jury Found '314 & '162 Patents To Be Infringed By AstraZeneca And Not Invalid, Awarded Plaintiffs $107.5M In Damages
AZNAstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
AZNAstraZeneca's Phase 3 SUPERNOVA trial shows sipavibart significantly reduces symptomatic COVID-19 in immunocompromised patients. The trial met primary endpoints, showing effectiveness against various SARS-CoV-2 variants.
AstraZeneca's High-level Results From SUPERNOVA Phase 3 Covid-19 Pre-exposure Prophylaxis Trial Showed Sipavibart (AZD3152) Reduced The Incidence Of Symptomatic Covid‑19 Vs. Control (Tixagevimab/Cilgavimab Or Placebo) In Immunocompromised Patients
AZNChina's Chengdu To Gradually Ease Covid Restrictions From Thursday
AZNUS Judge Dismisses Shareholder Lawsuit Over AstraZeneca's COVID-19 Vaccine Disclosures: Report
AZNCMS Says Updated Covid-19 Vaccines Providing Protection Against Omicron Variant Available At No Cost
AZNIMFINZI Plus Chemotherapy Further Improved Overall Survival Benefit In Advanced Biliary Tract Cancer In The TOPAZ-1 Phase III Trial, Reducing The Risk Of Death By 24% In Additional Follow-up; Will Present At ESMO
AZNAstraZeneca Announced TAGRISSO (osimertinib) Demonstrated 5.5-year Median Disease-free Survival in the Adjuvant Treatment of Patients with EGFR-mutated Lung Cancer; Data Presented at ESMO 2022
AZNAstraZeneca Announced Imfinzi and Tremelimumab With Chemotherapy Demonstrated Sustained Survival Benefit in Metastatic Non-small Cell Lung Cancer, Nearly Doubling the Number of Patients Alive After Three Years vs Chemotherapy
AZNAstraZeneca Announced Enhertu Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
AZNAstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
AZNAstraZeneca And Merck Announce Long-Term Follow Up Results From Phase 3 PAOLA-1 And SOLO-1 Trials
AZNGatehouse Bio Extends Its Partnership With AstraZeneca to Develop RNA Therapeutics for Heart Failure; Terms Not Disclosed
AZNFDA Accepts AstraZeneca's sBLA for Imfinzi (durvalumab) in biliary tract cancer (BTC) with Priority Review
AZNThe U.S. Food and Drug Administration (FDA) has accepted AstraZeneca's (NASDAQ: AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy and granted Priority Review for patients with locally advanced or metastatic biliary tract cancer (BTC).
AstraZeneca's Imfinzi/Chemo Combo Goes Under Priority FDA Review For Bile Duct Cancer
AZNAstraZeneca Announced Imfinzi Plus Chemotherapy Granted Priority Review in the Us for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial
AZNSVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $75
AZNFourth COVID-19 Shot? See Why Medical Professionals Are Skeptical
AZNMedical professionals are undecided on whether a fourth dose of the Covid-19 vaccine would benefit the wider population, as countries are beginning to offer the fourth dose to vulnerable groups.
Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales
AZNFollowing Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance.
AstraZeneca: Q1 Earnings Insights
AZNAstraZeneca (NASDAQ:AZN) reported its Q1 earnings results on Friday, April 29, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
AstraZeneca reported an EPS of $1.89.
AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook
AZNAstraZeneca Q1 EPS $1.89 Beat $1.70 Est; Revenue $11.39B Beat $10.99B Est
AZNSix US States Probing Mysterious Liver Inflammation In Kids: Bloomberg
AZNAt least six U.S. states are reporting confirmed or suspected cases of an unexplained, severe liver disorder in children.
Health officials in New York state and Wisconsin said they’re investigating reports of pediatric hepatitis that match a description released last week by the Centers for Disease Control and Prevention.
AstraZeneca Announced Ultomiris Approved in the US for Adults with gMG
AZN